--- title: "Allarity Therapeutics, Inc. (ALLR.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/ALLR.US.md" symbol: "ALLR.US" name: "Allarity Therapeutics, Inc." industry: "Biotechnology" datetime: "2026-05-21T11:53:19.756Z" locales: - [en](https://longbridge.com/en/quote/ALLR.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/ALLR.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/ALLR.US.md) --- # Allarity Therapeutics, Inc. (ALLR.US) ## Company Overview Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer. It is also developing stenoparib with temozolomide, a PARP and WNT inhibitor in combination with a DNA-alkylating chemotherapy agent, which is in a Phase 2 clinical trial for patients with relapsed small cell lung cancer; and stenoparib-DRP, a companion diagnostic product used to select patients for stenoparib treatment. | Item | Detail | |------|--------| | Industry | Biotechnology | | Exchange | US Market | | Website | [www.allarity.com](https://www.allarity.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-21T04:30:16.000Z **Overall: D (0.71)** **Industry**: Biotechnology | Metric | Value | |--------|-------| | Industry Ranking | 301 / 385 | | Industry Median | C | | Industry Average | C | - **Style**: Blend - Stocks in which the company has both growth and mature businesses. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 0.00% | | | Net Profit YoY | 53.14% | | | P/B Ratio | 3.41 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 23570280.20 | | | Revenue | 345000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -87.92% | E | | Profit Margin | -3260.58% | E | | Gross Margin | 100.00% | A | | Revenue YoY | 0.00% | D | | Net Profit YoY | 53.14% | B | | Total Assets YoY | 17.47% | A | | Net Assets YoY | -62.93% | E | | Cash Flow Margin | 147.81% | B | | OCF YoY | 0.00% | D | | Turnover | 0.01 | E | | Gearing Ratio | 80.18% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Allarity Therapeutics, Inc.", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "0.00%", "rating": "" }, { "name": "Net Profit YoY", "value": "53.14%", "rating": "" }, { "name": "P/B Ratio", "value": "3.41", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "23570280.20", "rating": "" }, { "name": "Revenue", "value": "345000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-87.92%", "rating": "E" }, { "name": "Profit Margin", "value": "-3260.58%", "rating": "E" }, { "name": "Gross Margin", "value": "100.00%", "rating": "A" }, { "name": "Revenue YoY", "value": "0.00%", "rating": "D" }, { "name": "Net Profit YoY", "value": "53.14%", "rating": "B" }, { "name": "Total Assets YoY", "value": "17.47%", "rating": "A" }, { "name": "Net Assets YoY", "value": "-62.93%", "rating": "E" }, { "name": "Cash Flow Margin", "value": "147.81%", "rating": "B" }, { "name": "OCF YoY", "value": "0.00%", "rating": "D" }, { "name": "Turnover", "value": "0.01", "rating": "E" }, { "name": "Gearing Ratio", "value": "80.18%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | -2.10 | 247/385 | - | - | - | | PB | 3.41 | 268/385 | 1.83 | 1.47 | 0.84 | | PS (TTM) | 68.32 | 242/385 | 69.21 | 66.24 | 59.21 | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A | | 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A | | 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A | | 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A | | 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A | ## Institutional View ### Analyst Rating Distribution > As of 2026-04-10T04:00:00.000Z Total Analysts: **1** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 1 | 100% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 1.49 | | Highest Target | 9.75 | | Lowest Target | 9.75 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ALLR.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ALLR.US/norm.md) - [Related News](https://longbridge.com/en/quote/ALLR.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ALLR.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**